Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (141-150 of 178) with videos related to

Pageof 18
Sort By:
Blood Advances|February 24, 2026
Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiomeLilli Sophie Sester, Iuliia Galeeva, Juliana de Castilhos, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Nature Medicine|July 6, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Pageof 18

Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
Blood Advances|February 24, 2026
Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiomeLilli Sophie Sester, Iuliia Galeeva, Juliana de Castilhos, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Nature Medicine|July 6, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Pageof 18